Breast Cancer Cells Transform Differently as Women Age, Study Reveals
Single-cell analysis shows aging reshapes the tumor microenvironment in breast cancer, with distinct molecular shifts by subtype and patient age.
Summary
Researchers analyzed bulk and single-cell transcriptomic data from thousands of breast cancer patients to reveal how aging changes the molecular makeup of tumor cells and their surrounding microenvironment. In triple-negative breast cancer (TNBC), older patients showed increased epithelial-mesenchymal transition in tumor cells and heightened inflammatory responses in cancer-associated fibroblasts. In estrogen receptor-positive (ER+) breast cancer, aging correlated with increased ESR1 expression and reduced metabolic activity in vascular and immune cells. Using a novel computational pipeline called ASPEN, and validating findings with spatial immunostaining across independent cohorts, the study identifies specific signaling pathways driving these age-related states — opening doors for age-tailored breast cancer therapies.
Detailed Summary
Breast cancer outcomes are paradoxically worse for both the youngest (<45) and oldest (>65) patients, yet the biological reasons remain poorly understood. This study addresses a critical gap: how does aging reshape the cellular and molecular landscape of breast tumors, and does this differ by subtype?
The researchers analyzed bulk transcriptomic data from METABRIC and TCGA databases, focusing on stage I–III TNBC/basal and ER+/luminal A breast cancers, stratified into 'younger' (<45 years) and 'older' (>65 years) groups. They then applied single-cell RNA sequencing (scRNA-seq) datasets from existing studies to dissect age-related differences at cell-type resolution across tumor cells, cancer-associated fibroblasts (CAFs), immune cells, and vascular cells.
To systematically extract and compare age-associated transcriptional programs across cell types and subtypes, the team developed the Age-Specific Program ENrichment (ASPEN) pipeline. This computational framework identified gene programs enriched in younger versus older patients within each cell population and breast cancer subtype. Key findings in TNBC included elevated epithelial-mesenchymal transition (EMT) signatures in tumor cells of younger patients, while older TNBC patients exhibited stronger inflammatory CAF responses. In ER+ breast cancer, older patients showed markedly increased ESR1 (estrogen receptor 1) expression in tumor cells and a broad suppression of metabolic gene programs in vascular endothelial and immune cells.
Cell-cell interactome analyses using ligand-receptor interaction tools revealed candidate signaling pathways — including inflammatory cytokine networks and matrix-remodeling signals — that likely drive these age-specific cell states. Spatial transcriptomics and immunohistochemical validation across independent clinical cohorts confirmed several of the computationally predicted findings, lending confidence to the biological relevance of the observations.
The study has meaningful clinical implications: age-related tumor microenvironment differences may help explain why standard therapies yield variable outcomes across age groups. Targeting EMT pathways in young TNBC patients, or modulating CAF inflammatory signaling in older TNBC patients, could represent age-adapted therapeutic strategies. Similarly, the metabolic suppression seen in immune and vascular cells of older ER+ patients may impair anti-tumor immunity or treatment response. The ASPEN pipeline itself is a generalizable resource for future aging-cancer research.
Key Findings
- ASPEN pipeline identified age-specific transcriptional programs across all major breast tumor cell types.
- Younger TNBC patients show higher epithelial-mesenchymal transition signatures in cancer cells.
- Older TNBC patients have increased inflammatory cancer-associated fibroblast gene programs.
- Older ER+ patients exhibit elevated ESR1 expression and reduced immune/vascular cell metabolism.
- Cell interactome analysis and spatial validation confirmed age-driven signaling pathway differences.
Methodology
The study integrated bulk transcriptomic data from METABRIC and TCGA with publicly available single-cell RNA-seq datasets, stratifying patients as younger (<45) or older (>65). A custom computational pipeline, ASPEN, was developed to identify age-associated gene programs at cell-type resolution; findings were validated using spatial transcriptomics and immunohistochemistry on independent clinical cohorts.
Study Limitations
The analyses rely on existing public datasets, which may have cohort biases and variable clinical annotation quality. Age stratification cutoffs (<45 and >65) create discrete groups that may not capture continuous aging biology. Causal relationships between age-related cell states and clinical outcomes require prospective experimental validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: